Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

R-006

Supelco

Risperidone solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C23H27FN4O2
CAS Number:
106266-06-2
Molecular Weight:
410.48
UNSPSC Code:
41116107
NACRES:
NA.24

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

CC1=C(CCN2CCC(CC2)c3noc4cc(F)ccc34)C(=O)N5CCCCC5=N1

InChI

1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3

InChI key

RAPZEAPATHNIPO-UHFFFAOYSA-N

Gene Information

human ... DRD2(1813) , HTR2A(3356) , HTR2C(3358)

General description

Risperidone, marketed as Risperdal®, Ridal, or Riscalin, is an atypical antipsychotic used to treat schizophrenia, bipolar disorder, and irritability in autistic children. This new Certified Snap-N-Spike® Solution is suitable for many LC/MS and GC/MS applications including forensic analysis, clinical toxicology, or urine drug testing.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Risperdal is a registered trademark of Johnson & Johnson
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Target Organs

Eyes,Central nervous system

Storage Class Code

3 - Flammable liquids

WGK

WGK 2

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 1

1 of 1

Risperidone Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1631

Risperidone

Zhiyun Wei et al.
Journal of clinical psychopharmacology, 33(2), 221-225 (2013-02-21)
Histamine interacts with histamine H4 receptor (HRH4) to impact antipsychotic response. Pharmacogenetic information about this receptor could therefore be useful in developing individualized therapy. The aim of this investigation was to clarify whether polymorphisms at human HRH4 gene alter risperidone
Vina M Goghari et al.
Schizophrenia research, 149(1-3), 149-155 (2013-07-09)
Atypical antipsychotic medications generally maintain or increase gray matter amount and functioning. First-episode psychosis patients have lower gray matter volume in the middle frontal gyrus, as well as worse performance on spatial working memory tasks compared to controls. This study
W Victor R Vieweg et al.
Psychopharmacology, 228(4), 515-524 (2013-07-03)
A recent publication asserted that even low-dose risperidone may induce corrected QT (QTc) interval prolongation up to 500 ms without drug-induced IKr blockade. We seek to better understand the complexity of any link between risperidone-induced/associated QTc interval prolongation and torsade de
Michael J Duhig et al.
Journal of paediatrics and child health, 49(1), 19-26 (2011-11-05)
This study aims to review the evidence for the efficacy of risperidone in the treatment of disruptive behavioural disorders (DBDs) in children and adolescents. Established databases were searched using the terms 'Risperidone and efficacy and children' and 'Risperidone and efficacy
Andrea Fagiolini et al.
Expert opinion on pharmacotherapy, 11(10), 1727-1740 (2010-05-22)
It is very rare for patients with bipolar disorder to have a single episode of mania or depression over a lifetime and the vast majority of these individuals need long-term prophylactic/maintenance treatment. However, treatment nonadherence is a major issue for
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service